Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Infectious Disease

Understanding Cytomegalovirus (CMV): Validation & Orientation

At a Glance

Cytomegalovirus (CMV) is an extremely common virus that most healthy adults carry without symptoms. Once contracted, CMV remains dormant in the body for life. It only poses a serious health risk to individuals with weakened immune systems, such as transplant recipients, and developing fetuses.

If you have recently heard the term Cytomegalovirus (CMV), you may feel overwhelmed or concerned. However, the first thing to understand is that you are not alone. CMV is a ubiquitous (found everywhere) virus that belongs to the beta-herpesvirus family—the same broad family of viruses that causes chickenpox and cold sores [1][2]. It is an incredibly common human infection that most people carry without ever knowing it [3].

A Common Human Companion

In the United States, more than half of all adults have been infected with CMV by age 40 [4]. Globally, the numbers are even higher; in many parts of the world, over 90% of the population carries the virus [5]. Because it is so widespread, a CMV-positive result is generally considered a “normal” finding for most healthy adults and is not a cause for alarm in a healthy immune system [6]. While the vast majority of healthy adults have no symptoms, a small number may experience a temporary, mono-like illness (fever, fatigue, sore throat) during a primary infection [3]. Otherwise, the virus goes completely unnoticed.

The “Hider”: Latency and Reactivation

The defining characteristic of CMV is its ability to establish latency [1]. This means that after the initial infection, the virus never truly leaves your body. Instead, it enters a “sleep” state where it remains quiet and hidden.

  • Where it hides: The virus primarily resides in CD34+ hematopoietic progenitor cells (immature cells in your bone marrow that eventually become blood cells) and myeloid cells (like monocytes and macrophages, which are types of white blood cells) [7].
  • The “Lytic-Latent Switch”: While the virus is latent, your immune system keeps it under control, and it does not cause symptoms or damage [8]. However, if the immune system is significantly weakened or “stressed” by severe inflammation, the virus can reactivate (wake up), begin replicating, and potentially cause disease [9][10].

Why Context Matters: The Three Vulnerable Groups

For the vast majority of people, CMV is a “silent passenger” that causes no trouble. However, for three specific groups, the virus can become a “bad actor” because their immune systems cannot effectively keep it in the latent state.

1. Transplant Recipients

Whether receiving a solid organ (like a kidney) or a stem cell transplant, these patients take immunosuppressive medications to prevent their body from rejecting the new graft [11]. Because these drugs “turn down” the immune system’s volume, they also accidentally lower the guards that keep CMV asleep. This can lead to tissue-invasive disease, where the virus attacks the lungs, liver, or gastrointestinal tract [12][13].

2. Fetuses and Newborns

If a person catches CMV for the first time while pregnant, or if a latent infection reactivates, the virus can pass to the developing baby. This is known as congenital CMV [3]. Because a fetus’s immune system is still developing, the virus can interfere with growth, particularly affecting hearing and neurological development [14].

3. People Living with HIV/AIDS

In individuals with advanced HIV, the immune system’s CD4+ T-cells (the “generals” of the immune system) can become very low [15]. Without these cells to coordinate a defense, CMV can reactivate and cause serious issues, most notably CMV retinitis, an infection in the eye that can lead to vision loss if not managed [16].

Moving Forward

Understanding CMV is about understanding your own immune context. For most, it is a dormant part of their biological history. For those in high-risk groups, modern medicine uses active surveillance (regular blood tests like PCR to check for viral DNA) and prophylactic (preventive) treatments to ensure the “silent passenger” stays quiet [17][18]. If you need help understanding your lab results, see our guide on Pathology & Testing.

Common questions in this guide

Is it normal to test positive for Cytomegalovirus (CMV)?
Yes, testing positive for CMV is very common and generally considered a normal finding for healthy adults. Because the virus is so widespread globally, most people carry it without ever experiencing symptoms or knowing they have it.
Does CMV ever go away completely?
No, CMV never truly leaves your body after the initial infection. Instead, it enters a dormant state called latency, where it hides quietly in your cells while your immune system keeps it under control.
Who is at high risk for CMV complications?
CMV primarily poses risks to individuals with weakened immune systems, such as organ or stem cell transplant recipients, and people living with advanced HIV. It can also cause developmental issues in fetuses and newborns if passed from the mother during pregnancy.
How do doctors monitor CMV in high-risk patients?
Doctors typically use active surveillance, which involves regular blood tests like a PCR test to check for viral DNA in your system. This helps them detect if the dormant virus has started to reactivate so they can begin preventive treatments.
What are the symptoms of a CMV infection?
Most healthy people have no symptoms, but some may experience a temporary illness similar to mononucleosis, featuring fever, fatigue, and a sore throat. In individuals with severely weakened immune systems, a reactivated infection can cause more serious issues like blurred vision, breathing problems, or persistent digestive issues.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my current CMV status (seropositive or seronegative), and how was it determined?
  2. 2.Based on my specific health situation (e.g., transplant, pregnancy, or immune status), am I at high risk for the virus becoming active?
  3. 3.If the virus is currently latent, what specific symptoms should I watch for that might signal it has reactivated?
  4. 4.How will you monitor the virus in my system—will you use regular blood tests (like PCR) or only test if I have symptoms?
  5. 5.Are there specific precautions I should take to avoid either catching a new strain or reactivating the virus I already have?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on "The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts".

    Mercorelli B, Luganini A, Palù G, et al.

    Viruses 2019; (11(2)) doi:10.3390/v11020117.

    PMID: 30699923
  2. 2

    Cytomegalovirus, Macrophages and Breast Cancer.

    Pasquereau S, Al Moussawi F, Karam W, et al.

    The open virology journal 2017; (11()):15-27 doi:10.2174/1874357901711010015.

    PMID: 28567162
  3. 3

    Human cytomegalovirus and neonatal infection.

    Lawrence SM

    Current research in microbial sciences 2024; (7()):100257 doi:10.1016/j.crmicr.2024.100257.

    PMID: 39070527
  4. 4

    Estimated cytomegalovirus seroprevalence in the general population of the United States and Canada.

    Dana Flanders W, Lally C, Dilley A, Diaz-Decaro J

    Journal of medical virology 2024; (96(3)):e29525 doi:10.1002/jmv.29525.

    PMID: 38529529
  5. 5

    Cytomegalovirus seroprevalence among blood donors: a systematic review and meta-analysis.

    Adane T, Getawa S

    The Journal of international medical research 2021; (49(8)):3000605211034656 doi:10.1177/03000605211034656.

    PMID: 34382466
  6. 6

    Neuron-restricted cytomegalovirus latency in the central nervous system regulated by CD4+ T-cells and IFN-γ.

    Krstanović F, Mihalić A, Rashidi AS, et al.

    Journal of neuroinflammation 2025; (22(1)):95 doi:10.1186/s12974-025-03422-6.

    PMID: 40158177
  7. 7

    Rethinking human cytomegalovirus latency reservoir.

    Schwartz M, Stern-Ginossar N

    Annals of the New York Academy of Sciences 2023; (1524(1)):30-36 doi:10.1111/nyas.14994.

    PMID: 37026581
  8. 8

    A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells.

    Poole E, Carlan da Silva MC, Huang C, et al.

    mBio 2021; (12(3)):e0022721 doi:10.1128/mBio.00227-21.

    PMID: 34061599
  9. 9

    Regulation of the MIE Locus During HCMV Latency and Reactivation.

    Dooley AL, O'Connor CM

    Pathogens (Basel, Switzerland) 2020; (9(11)) doi:10.3390/pathogens9110869.

    PMID: 33113934
  10. 10

    Human Cytomegalovirus UL78 is a Nuclear-Localized GPCR Necessary for Efficient Reactivation from Latent Infection in CD34+ Hematopoietic Progenitor Cells.

    Medica S, Diggins NL, Denton M, et al.

    bioRxiv : the preprint server for biology 2025; doi:10.1101/2025.06.02.657350.

    PMID: 40501644
  11. 11

    Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy.

    Lin RY, Anderson AD, Natori Y, et al.

    Blood advances 2024; (8(14)):3813-3822 doi:10.1182/bloodadvances.2024012922.

    PMID: 38838226
  12. 12

    Sensitivity of blood and tissue diagnostics for gastrointestinal cytomegalovirus disease in solid organ transplant recipients.

    Fisher CE, Alexander J, Bhattacharya R, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2016; (18(3)):372-80 doi:10.1111/tid.12531.

    PMID: 27004439
  13. 13

    Cytomegalovirus infection and cardiovascular outcomes in abdominal organ transplant recipients: A systematic review and meta-analysis.

    Arvanitis P, Davis MR, Farmakiotis D

    Transplantation reviews (Orlando, Fla.) 2024; (38(4)):100860 doi:10.1016/j.trre.2024.100860.

    PMID: 38815340
  14. 14

    Congenital cytomegalovirus infection diagnostics and management.

    Pinninti S, Boppana S

    Current opinion in infectious diseases 2022; (35(5)):436-441 doi:10.1097/QCO.0000000000000874.

    PMID: 35984001
  15. 15

    Retrospective study of cytomegalovirus retinitis complicated with acquired immunodeficiency syndrome.

    Huang G, Jiang Q, Li M, et al.

    International journal of clinical and experimental medicine 2015; (8(6)):9537-42.

    PMID: 26309620
  16. 16

    Investigation of the infection route of HIV-associated cytomegalovirus retinitis.

    Cai J, Xie ZK, Tang DY, et al.

    International journal of ophthalmology 2025; (18(3)):478-486 doi:10.18240/ijo.2025.03.15.

    PMID: 40103955
  17. 17

    Immune Monitoring for CMV in Transplantation.

    Yong MK, Lewin SR, Manuel O

    Current infectious disease reports 2018; (20(4)):4 doi:10.1007/s11908-018-0610-4.

    PMID: 29542023
  18. 18

    Impact of electronic health record-based, pharmacist-driven valganciclovir dose optimization in solid organ transplant recipients.

    Hensler D, Richardson CL, Brown J, et al.

    Transplant infectious disease : an official journal of the Transplantation Society 2018; (20(2)):e12849 doi:10.1111/tid.12849.

    PMID: 29360250

This page provides a general overview of Cytomegalovirus (CMV) for educational purposes. Always consult an infectious disease specialist or your primary care provider regarding your specific risk factors, symptoms, and testing needs.

Get notified when new evidence is published on Cytomegalovirus Infection.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.